Syntekabio USA
Provider of AI-driven drug discovery services and computational biology platforms. Offers large-scale virtual screening, physics-based molecular docking, computational antibody and neoantigen discovery, and end-to-end discovery support from hit finding through IND-enabling activities. Maintains high-performance compute infrastructure and claims validation via external collaborations and benchmark comparisons.
Industries
N/A
Nr. of Employees
small (1-50)
Syntekabio USA
Samunan-ro 92, Gwanghwamun Official Building #1708, Jongno-gu, Seoul, Republic of Korea
Products
Language-model-based virtual screening service
High-throughput virtual screening service that applies language-model approaches to prioritize billions of compounds for a given target.
Automated binding-pose prediction and flexible docking tools
Computational docking toolset for binding-pose prediction and flexible docking with benchmarked performance for pose accuracy.
Automated lead generation and optimization workflows
Algorithmic workflows that propose and optimize lead compounds to improve potency and developability.
Computational biologics discovery and neoantigen prediction services
In silico antibody and neoantigen identification services coupled with peptide synthesis and immunoassay validation workflows.
Language-model-based virtual screening service
High-throughput virtual screening service that applies language-model approaches to prioritize billions of compounds for a given target.
Automated binding-pose prediction and flexible docking tools
Computational docking toolset for binding-pose prediction and flexible docking with benchmarked performance for pose accuracy.
Automated lead generation and optimization workflows
Algorithmic workflows that propose and optimize lead compounds to improve potency and developability.
Computational biologics discovery and neoantigen prediction services
In silico antibody and neoantigen identification services coupled with peptide synthesis and immunoassay validation workflows.
Services
Programmatic offering that funds initial computational discovery and feasibility work so clients can evaluate targets without upfront costs.
Integrated discovery program intended to deliver hits, optimized leads and IND-enabled candidates through combined computational and experimental workflows.
Rapid feasibility analysis of a client-provided protein target to determine tractability before committing to a full discovery program.
Programmatic offering that funds initial computational discovery and feasibility work so clients can evaluate targets without upfront costs.
Integrated discovery program intended to deliver hits, optimized leads and IND-enabled candidates through combined computational and experimental workflows.
Rapid feasibility analysis of a client-provided protein target to determine tractability before committing to a full discovery program.
Expertise Areas
- AI-driven virtual screening
- Physics-based molecular docking
- Computational antibody discovery
- Neoantigen prediction for immuno-oncology
Key Technologies
- Language-model-based virtual screening
- Flexible molecular docking
- AI-driven lead optimization algorithms
- Computational antibody design
News & Updates
Participation and presentations at industry conferences to showcase AI-driven drug discovery methods and platform capabilities.
Collaboration with an external research institution produced candidate molecules for lung disease targets with in silico efficacy signals within ~5 months and plans for clinical advancement.
Automated binding-pose prediction tool reported RMSD <2.5 Å and higher success rates versus selected industry docking tools in internal benchmarks.
Case studies reported multi-fold potency improvements for targets such as CLK2, IDO/TDO dual inhibitors and FLT3 across optimization campaigns.
Support of a partner's proprietary cancer vaccine program that received US FDA clearance to proceed with a phase 1 trial, based on patient-specific neoantigen identification and validation workflows.
Participation and presentations at industry conferences to showcase AI-driven drug discovery methods and platform capabilities.
Collaboration with an external research institution produced candidate molecules for lung disease targets with in silico efficacy signals within ~5 months and plans for clinical advancement.
Automated binding-pose prediction tool reported RMSD <2.5 Å and higher success rates versus selected industry docking tools in internal benchmarks.
Case studies reported multi-fold potency improvements for targets such as CLK2, IDO/TDO dual inhibitors and FLT3 across optimization campaigns.
Support of a partner's proprietary cancer vaccine program that received US FDA clearance to proceed with a phase 1 trial, based on patient-specific neoantigen identification and validation workflows.